ALBANY, N.Y. & MILWAUKEE--(BUSINESS WIRE)--GE (NYSE: GE) today announced it has entered into a new worldwide licensing agreement with Bionime, a global leader in biotechnology medical testing, to provide new GE-branded solutions for the diabetes market.
According to the World Health Organization, an estimated 346 million people worldwide have diabetes. Type 2 diabetes is the fastest growing chronic disease in the world. Through this agreement, Bionime will deliver GE-branded blood glucose monitors, test strips, kits and related diabetes accessories.
The first product to be launched is the GE100 Blood Glucose Monitoring System, available now through durable medical equipment suppliers and on retail shelves in 2012. The GE100 utilizes advanced patented strip technology to achieve a high level of accuracy and precision and a unique, innovative strip design that makes it easier to use and more sanitary for the consumer than current similar offerings. In addition, patented True Auto Coding Technology eliminates the need to code each strip lot without sacrificing the accuracy of the readings. The GE100 provides an easy, clean and accurate way to test blood glucose levels of people living with diabetes.
“We are very excited to work with Bionime to provide innovative blood glucose monitoring for diabetes patients worldwide,” said David Ataide, General Manager, Strategic & Customer Initiatives, GE Healthcare. “Managing diabetes care is critical to the health of our society, and we believe this an important first step for our business.”
“Bionime’s vision is that with our ‘peace of mind’ medical devices, we offer solutions to patients to accurately manage and control their own health,” noted Roy Huang, Chairman, Bionime Corporation. “By joining forces with GE, we can grow this vision by developing new offerings and widening the market for Bionime’s products.”
For more information on the GE100 Blood Glucose Monitoring System, please visit www.gediabetes.com.
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
For our latest news, please visit http://newsroom.gehealthcare.com
Established in April 2003, BIONIME is specialized in the business of biotechnology and medical testing. BIONIME integrates top-tier expertise in medical science, chemistry, electronics and precision engineering to commercialize our patented noble metal, biosensor technology used in our meters and test strips. Today, BIONIME employs more than 500 people and operates 4 subsidiaries in Europe, the Americas, Australia and Asia. Our products have been shown to meet or exceed the highest standards of accuracy and precision in numerous independent studies published in leading international clinical journals. Bionime products are distributed worldwide and are available in all the major markets. For more information please visit our Web Site at www.bionime.com.